Essen Amyloidosis Registry Study
Part of Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This study collects information from people with suspected or confirmed amyloidosis. The goal is to learn more about the condition and improve patient care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have suspected or confirmed amyloidosis (any type).
- You are 18 years old or older.
- You are willing and able to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tissue samples and health data from people with amyloidosis to build a biobank and registry. Researchers hope this will help improve future diagnosis and treatment.
This study aims to find, describe, and track people with cardiac amyloidosis over time. It uses MRI scans and other tests to better understand the condition, which may help guide future treatment.
This study collects health information from people who may have amyloidosis or who already have a confirmed diagnosis. It aims to better understand amyloidosis in real-world care across European centers, which can help future patients and treatments.
This trial is a registry that collects health information from people with amyloidosis, including cases where the heart may be involved. Sharing your medical details can help researchers learn how this condition affects patients and may guide future care.
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
This study is a registry that collects information from people with cardiac amyloidosis. It helps doctors learn more about the condition and how to better treat it.
Hear when a new Amyloidosis; Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.